AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 70(3), 2004, pp. 273-277
Copyright © 2004 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GATCHALIAN, S.
Right arrow Articles by DESAUZIERS, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GATCHALIAN, S.
Right arrow Articles by DESAUZIERS, E.
Related Collections
Right arrow Vaccine
Right arrow Paramyxoviruses

IMMUNOGENICITY AND SAFETY OF A VARICELLA VACCINE (OKAVAXTM) AND A TRIVALENT MEASLES, MUMPS, AND RUBELLA VACCINE (TRIMOVAXTM) ADMINISTERED CONCOMITANTLY IN HEALTHY FILIPINO CHILDREN 12–24 MONTHS OLD

SALVACION GATCHALIAN, CHARISSA TABORA, NANCY BERMAL, DIDIER LEBOULLEUX, AND ERIC DESAUZIERS
Research Institute for Tropical Medicine, Manila, The Philippines, Department of Pediatrics, University of the Philippines, General Hospital, Manila, The Philippines; Aventis Pasteur, Lyon, France

The immunogenicity and safety of OkavaxTM varicella vaccine, when administered concomitantly with TrimovaxTM measles, mumps, and rubella (MMR) vaccine, were assessed in 300 Filipino children 12–24 months old. Three groups received Okavax only, Trimovax only, or both vaccines concomitantly. In sera obtained six weeks after vaccination, high varicella antibody geometric mean titers (GMTs) (115 and 79.8 mIU/mL, respectively) and seroconversion rates (>= 91.9%) were similar for Okavax given alone or concomitantly with Trimovax. High MMR GMTs and seroconversion rates (mumps >= 94.6%, measles and rubella >= 98.6%) were not affected by concomitant administration of Trimovax with Okavax. Solicited local and systemic reactions recorded by parents were slightly more numerous after concomitant administration, but the majority of all reactions were mild and transient. The good tolerance and high immunogenicity observed supports the concomitant administration of Okavax and Trimovax to children in their second year of life to protect against four life-threatening diseases while simplifying childhood immunization programs.

Received October 14, 2002. Accepted for publication October 12, 2003.

Acknowledgments: We are grateful to V. Canouet, Professor M. Crisostomo, C. Deroche, I. Durot, and R. Mate for their expertise in the performance of this study.

Financial support: This study was supported by Aventis Pasteur (Lyon, France).

Disclaimer: Didier Leboulleux and Eric Desauziers are employees of Aventis Pasteur.

Authors’ addresses: Salvacion Gatchalian, Charissa Tabora, and Nancy Bermal, Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntilupa, The Philippines. Didier Leboulleux, Aventis Pasteur, 24/F, DCH Commercial Centre, 25 Westlands Road, Quarry Bay, Hong Kong, Telephone: 852-2506-8421. Eric Desauziers, Aventis Pasteur, 2 Avenue Pont Pasteur, 69007 Lyon, France, Telephone: 33-4-37-37-73-84.

Reprint requests: Salvacion Gatchalian, Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntilupa, The Philippines, Telephone: 63-2-809-7599, Fax: 63-2-842-2245, E-mail: edsal{at}impactnet.com.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Tropical Medicine and Hygiene.